Evidence map›Paper›PMID 28393206›Full record

ArticleMolecular medicine reports2017

Prognostic role of TPL2 in early‑stage non‑small cell lung cancer.

Laura Boldrini, Mirella Giordano, Adele Servadio, Cristina Niccoli, Pietro Bertoglio, Marco Lucchi, Franca Melfi, Alfredo Mussi, Gabriella Fontanini

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular medicine reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Laura BoldriniDepartment of Surgical, Medical, Molecular Pathology and Critical Care, University of Pisa, I‑56126 Pisa, Italy.
Mirella GiordanoDepartment of Surgical, Medical, Molecular Pathology and Critical Care, University of Pisa, I‑56126 Pisa, Italy.
Adele ServadioDepartment of Surgical, Medical, Molecular Pathology and Critical Care, University of Pisa, I‑56126 Pisa, Italy.
Cristina NiccoliDepartment of Surgical, Medical, Molecular Pathology and Critical Care, University of Pisa, I‑56126 Pisa, Italy.
Pietro BertoglioDepartment of Surgical, Medical, Molecular Pathology and Critical Care, University of Pisa, I‑56126 Pisa, Italy.
Marco LucchiDepartment of Surgical, Medical, Molecular Pathology and Critical Care, University of Pisa, I‑56126 Pisa, Italy.
Franca MelfiUnit of Thoracic Surgery, Azienda Ospedaliero‑Universitaria Pisana, I‑56126 Pisa, Italy.
Alfredo MussiDepartment of Surgical, Medical, Molecular Pathology and Critical Care, University of Pisa, I‑56126 Pisa, Italy.
Gabriella FontaniniDepartment of Surgical, Medical, Molecular Pathology and Critical Care, University of Pisa, I‑56126 Pisa, Italy.
University of Pisa · ITAzienda Ospedaliera Universitaria Pisana · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non‑small cell lung cancer (NSCLC) accounts for ~70% of all lung cancer‑associated mortalities worldwide. The serine/threonine protein kinase tumor progression locus 2 [TPL2/MAP3 kinase 8 (MAP3K8)] may impact oncogenic events; however the role of TPL2 in lung carcinogenesis remains unclear. The present study was focused on the potential prognostic role of TPL2 in 101 patients with early‑stage NSCLC. Since TPL2 is a potential target of miR‑21, the association between TPL2 and miR‑21 expression was also examined. TPL2 and miR‑21 mRNA expression was quantified using reverse transcription quantitative polymerase chain reaction (RT‑qPCR). TPL2 protein levels were evaluated by immunohistochemistry (IHC). The present study identified that the mRNA expression of TPL2 was low in 52/101 (51%) cases and high in 49/101 (49%) cases. IHC analysis of TPL2 protein expression often demonstrated identical mRNA results. No statistically significant associations were observed between the mRNA expression of TPL2 and the predominant clinicopathological characteristics of the patients with NSCLC, as well as identifying no association between TPL2 and miR‑21. TPL2 mRNA expression was significantly higher in patients with NSCLC with good prognosis (disease‑free interval P=0.009; overall survival P=0.024), when compared with those of poor prognosis. Focusing on the difference in mRNA expression of TPL2 among the adenocarcinomas in affected patients, TPL2 was more highly expressed in lepidic adenocarcinomas compared with in the other subtypes (P=0.012). The present study is the first examination, to the best of our knowledge, of TPL2 in early‑stage NSCLC in relation to miR‑21, and in different adenocarcinoma subtypes. Future studies must clarify the mechanism by which TPL2 is involved in lung carcinogenesis due to its important translational implications.

Indexed as

Biomarkers, TumorAgedAged, 80 and overCarcinoma, Non-Small-Cell LungFemaleGene ExpressionHumansKaplan-Meier EstimateLung NeoplasmsMaleMAP Kinase Kinase KinasesMicroRNAsMiddle AgedNeoplasm GradingNeoplasm StagingPrognosisBiomarkers, TumorMAP3K8 protein, humanMAP Kinase Kinase KinasesMicroRNAsMIRN21 microRNA, humanProto-Oncogene Proteins

Identifiers

PMID28393206
PMCPMC5436291
OpenAlexW2604761264

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.